|
Aug 11
|
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 11
|
4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
|
|
Aug 6
|
4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
|
|
Jul 31
|
4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update
|
|
Jul 28
|
AAV for the Hereditary Retinal Diseases Market Competitive Landscape Report 2025 | Novartis, MeiraGTx, 4D Molecular Therapeutics, and Beacon Therapeutics Lead the Charge in Innovative Therapies
|
|
Jul 24
|
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists
|
|
Jul 21
|
BBOT Appoints Industry Veteran Uneek Mehra as Chief Financial Officer
|
|
Jul 2
|
4D Molecular Therapeutics Accelerates Wet AMD Trial, Cuts Jobs to Offset Costs
|
|
Jul 2
|
4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution
|
|
May 16
|
4DMT Announces New Employment Inducement Grants
|
|
May 2
|
FDA awards RMAT status to 4DMT diabetic macular oedema therapy
|
|
May 1
|
4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME
|
|
Apr 22
|
Discover Fractyl Health And 2 More Promising Penny Stocks
|
|
Apr 1
|
Biotech stocks slide as Marks resignation seen being negative for sector
|
|
Sep 5
|
4DMT Announces Presentations at Upcoming Retina Conferences
|
|
Sep 3
|
4DMT to Participate in the 2024 Cantor Global Healthcare Conference
|
|
Aug 27
|
4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
|
|
Jun 24
|
4D Molecular Therapeutics Says US FDA Clears its IND Application for Potential Geographic Atrophy Treatment
|
|
Jun 24
|
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
|
|
Jun 18
|
4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
|